74 related articles for article (PubMed ID: 7658726)
1. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.
Terpstra W; Prins A; Visser T; Wognum B; Wagemaker G; Löwenberg B; Wielenga J
Leukemia; 1995 Sep; 9(9):1573-7. PubMed ID: 7658726
[TBL] [Abstract][Full Text] [Related]
2. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
3. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.
Bonnet D; Bhatia M; Wang JC; Kapp U; Dick JE
Bone Marrow Transplant; 1999 Feb; 23(3):203-9. PubMed ID: 10084250
[TBL] [Abstract][Full Text] [Related]
4. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
5. Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
Lumkul R; Gorin NC; Malehorn MT; Hoehn GT; Zheng R; Baldwin B; Small D; Gore S; Smith D; Meltzer PS; Civin CI
Leukemia; 2002 Sep; 16(9):1818-26. PubMed ID: 12200698
[TBL] [Abstract][Full Text] [Related]
6. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
Uesato N; Fukui K; Maruhashi J; Tojo A; Tajima N
Exp Hematol; 2006 Oct; 34(10):1385-92. PubMed ID: 16982331
[TBL] [Abstract][Full Text] [Related]
7. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias.
Cesano A; Hoxie JA; Lange B; Nowell PC; Bishop J; Santoli D
Oncogene; 1992 May; 7(5):827-36. PubMed ID: 1570153
[TBL] [Abstract][Full Text] [Related]
8. Engraftment of SCID mice by human bone marrow hematopoietic cells cultured in vitro: an in vivo model for human gene transfer.
Spence SE; Keller JR; Ruscetti FW; Czarra KT; Gooya JM; Funakoshi S; Longo DL; Murphy WJ
Leukemia; 1995 Oct; 9 Suppl 1():S43-7. PubMed ID: 7475312
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
Wiley JM; Yeager AM
Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
[TBL] [Abstract][Full Text] [Related]
10. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
11. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
Monaco G; Konopleva M; Munsell M; Leysath C; Wang RY; Jackson CE; Korbling M; Estey E; Belmont J; Andreeff M
Stem Cells; 2004; 22(2):188-201. PubMed ID: 14990858
[TBL] [Abstract][Full Text] [Related]
12. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
13. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
[TBL] [Abstract][Full Text] [Related]
15. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
16. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
Rombouts WJ; Martens AC; Ploemacher RE
Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
[TBL] [Abstract][Full Text] [Related]
17. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.
Cheung AM; Wan TS; Leung JC; Chan LY; Huang H; Kwong YL; Liang R; Leung AY
Leukemia; 2007 Jul; 21(7):1423-30. PubMed ID: 17476279
[TBL] [Abstract][Full Text] [Related]
18. Growth of primary human acute leukemia in severe combined immunodeficient mice.
De Lord C; Clutterbuck R; Titley J; Ormerod M; Gordon-Smith T; Millar J; Powles R
Exp Hematol; 1991 Oct; 19(9):991-3. PubMed ID: 1893976
[TBL] [Abstract][Full Text] [Related]
19. Effect of sublethal total body irradiation on acute graft-versus-host disease and graft-versus-leukemia effect in SCID mice.
Sakai R; Maruta A; Yanoma S; Shimizu A; Harada M; Nakamura Y; Kodama F; Okubo T
Bone Marrow Transplant; 1997 Aug; 20(3):183-9. PubMed ID: 9257885
[TBL] [Abstract][Full Text] [Related]
20. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
